LUNAR: a randomized phase 2 study of 177 Lutetium-PSMA neoadjuvant to ablative radiotherapy for oligorecurrent prostate cancer (clinical trial protocol)

By sjmartinez • February 17, 2023

Ma TM, Czernin J, Felix C, Alano R, Wilhalme H, Valle L, Steinberg ML, Dahlbom M, Reiter RE, Rettig MB, Cao M, Calais J, Kishan AU. LUNAR: a randomized phase 2 study of ¹⁷⁷Lutetium-PSMA neoadjuvant to ablative radiotherapy for oligorecurrent prostate cancer (clinical trial protocol). BJU Int. 2023 Feb 16. doi: 10.1111/bju.15988. Epub ahead of print. PMID: 36797449.

Tags: 177Lu-PNT2002, Hematology/Oncology, lutetium-177, metastatic hormone sensitive prostate cancer, oligorecurrent, Progression-free survival, prostate cancer, prostate-specific membrane antigen, Publications, Stereotactic Body Radiation Therapy, trial protocol, Veterans Administration

Risk factors of immune-related adverse events in patients with early-stage breast cancer: Findings from a multi-institutional retrospective study

LeVee A, Jacob S, Fisch S, Face C, Chengappa M, Chaudhry S, Baclig N, Soliman A, Ruel N, Wong M, Tsai K, Kang I, Kordic[...]

Recurrent prostate adenocarcinoma after radical prostatectomy: Principles of multidisciplinary management across a spectrum of disease

Kishan AU, Zekster Y, Singer AE, Taparra K, Valle LF, Steinberg ML, Nickols NG, Reiter RE, Czernin J, Calais J, Lee JK, Hardesty LR, Rettig[...]

Divergent evolution in bilateral prostate cancer: a case study

Haas R, Huang RR, Weiner AB, Patel Y, Liu LY, Yamaguchi TN, Agrawal R, Boutros PC, Reiter RE. Divergent evolution in bilateral prostate cancer: a[...]